To mark World Malaria Day 2023, Malaria No More UK, Conservative Home and the All-Party Parliamentary Group (APPG) for Malaria and Neglected Tropical Diseases (NTDs), brought together scientists, MPs, Peers, supporters, and campaigners to highlight the importance of working together to end malaria.

IVCC attended an evening reception, hosted by Baroness Liz Sugg at the House of Lords. During the event, Louise Marston, an early career researcher affiliated with Target Malaria, highlighted the importance of innovation, along with research and development to end malaria. Peter Sands, Executive Director of The Global Fund, spoke about the growing challenges facing malaria eradication: including climate change and conflict. He stressed the importance of continued commitment to accelerate the progress toward zero malaria. To close, attendees heard from Olympic medallist and malaria survivor, Anyika Onuora, who described her experience of falling ill with malaria ahead of the 2016 Rio Olympics and the importance of continued investment to end malaria.

You can read more about the event and its participants in this Twitter thread by APPG on Malaria and NTDs.

Earlier in the day, IVCC CEO, Justin McBeath joined Andrew Mitchell (MP), Minister of State for Development and Africa for the United Kingdom, at a roundtable event, hosted by Malaria No More UK and Conservative Home.

The event raised the profile of Product Development Partnerships (PDPs) and their critical role in driving public-private partnerships to develop new health products for malaria elimination. David Reddy, CEO of Medicines of Malaria Venture (MMV) and Fiona Smith-Laittan, VP Global Health at GSK, also attended the event, along with United Kingdom government representatives such as James Sunderland MP, member of the APPG on Malaria and NTDs and Parliamentary Private Secretary (PPS) to the Home Secretary and Baroness Liz Sugg.

Image: Members of UK Parliament and House of Lords stand with (L to R), Baroness Lizz Sugg, Anyika Onuora, Louise Marston and Peter Sands. Credit: Malaria No More UK / Freya Turner.

IVCC’s External Scientific Advisory Committee (ESAC) welcomes two new experts, Dr Egon Weinmueller and Dr Samwel Okello. They join following a ‘call for experts’ in the development and manufacturing of insecticide-treated nets (ITNs).

The ESAC provides expert specialist technical assessments of IVCC’s portfolio of products, including project selection, transition, and termination. They provide advice to the IVCC management team during periodic reviews of the projects. Membership of the ESAC is through nomination of candidates with the required expertise.

Dr Egon Weinmueller has a PhD in Agriculture, International Trade and Policy. He is member of RBM VCWG. Egon retired from BASF after a career including Regional Management responsibilities for BASF Agricultural Products Division in various parts of the world and as head of the BASF Global Public Health unit in developing and bringing new products to market for indoor residual spraying (IRS) and ITNs.

Dr Samwel Okello brings 10 years of research experience in vector-borne diseases. He is currently involved in developing and improving technologies that save lives, including Long-Lasting Insecticidal Nets, Indoor Residual Sprays, Larvicides and Spatial Repellents. Samwel brings a wealth of experienced in evaluation of vector control products in laboratory and semi-field studies using standard WHO protocols. He formerly worked for International Center of Insect Physiology and Ecology as a research fellow in arbovirus research.

More details on the role and responsibilities of ESAC members, visit ivcc.com/research-development/esacs/

Dr Egon Weinmueller

Dr Samwel Okello

Download the Tech Updates highlighting vector biology and control news, publications and resources.

Given the breadth of vector control-related literature, we are unable to include all relevant work. These updates are intended to focus primarily on Anopheles biology and a subset of control topics with global relevance. Any views expressed in the updates do not necessarily reflect the views or opinions of IVCC. In many cases, we directly quote sections of published work. Mention of trade names or commercial products is solely for the purpose of providing specific information and does not imply recommendation or endorsement by IVCC or its funders.

Today, April 25^th,  we recognise World Malaria Day. It is an occasion to highlight the impact that this disease has on the under-served populations in endemic countries; to galvanise global efforts to end malaria and emphasise the need for sustained political commitment and continued investment for malaria control and elimination.

Since the year 2000, the scale-up of interventions in countries, supported by global partnerships and sustained investment, has transformed the fight against malaria – preventing 2 billion malaria cases, saving 11.7 million lives, and putting eradication within reach.

However, significant challenges lie ahead. Insecticide and drug resistance, new biological threats, the impact of climate change and humanitarian emergencies, as well as funding gaps and pressure on resources threaten to stall progress toward malaria eradication goals.

The theme of this year’s World Malaria Day, ‘Innovate, Invest and Implement’, highlights the role that innovation plays, across the malaria community, to address the future challenges.

IVCC has had the responsibility of steering investments from various funding organisations over the past 15+ years into the development and delivery of new vector control tools, in partnership with industry.

Investments over the last decade have been successful, with new products (both in ITNs and IRS insecticides) developed and deployed and delivering impact in countries.

Insecticide resistance remains one of the biggest threats to achieving malaria elimination. Industry engagement and support via partnership with IVCC, have delivered innovations to address this threat.

Products such as the recently WHO-PQ listed VECTRON™ T500, a new indoor residual spray product, developed by Mitsui Chemicals Crop & Life Solutions, Inc. containing TENEBENAL™; Interceptor® G2 from BASF, a dual active ingredient net for which a WHO-GMP Policy Recommendation was just finalised; and previously WHO-PQ Listed products such as Actellic^®300CS (co-developed by Syngenta), SumiShield™ 50WG (developed by Sumitomo Chemical) and Fludora® Fusion (developed by Bayer), contain different modes of action which can be rotated by country malaria control programs, expand the available toolbox, and are critical to preserve the long-term effectiveness of insecticide-based vector control interventions.

The pipeline for the future also shows promise; particularly for resistance management – with some brand-new insecticide modes of action potentially available for use on ITNs. But it is by no means certain. Solutions to address other threats (e.g. residual transmission and outdoor biting) are needed.

Technically, it is feasible to address some of these challenges – we know how to develop and deliver the needed innovation, but it will take continued engagement and/or investment from all relevant sectors. We must deliver on the current pipeline of existing tools and at the same time identify new solutions to address emerging challenges. It is critical that this is done together with country programs and implementing partners to ensure local relevance and impact amongst the countries and people that need them.

Where there are significant economic barriers to product innovation for industry, incentives are needed to encourage innovators to support the development of public health tools. The signing of the US EPA Vector Expedited Review Voucher (VERV), championed by IVCC following a policy proposal by Duke University, into law in late 2022 is an example of an initiative to stimulate investment in the development of innovative vector control solutions to help advance malaria elimination.

Market access activities, such as the catalytic market shaping work under the Unitaid and Global Fund supported New Nets Project (NNP), are a crucially important for introducing and implementing new innovation. The NNP laid the foundation for ensuring equitable and affordable access to new dual active ingredient nets such as Interceptor® G2 and Royal Guard® (developed by Disease Control Technologies).  As we move toward the introduction of novel interventions to address challenges in the future, that there will be benefits to, indeed a need for, similar approaches.

On this World Malaria Day, IVCC highlights the challenges on the road to malaria elimination, what role vector control plays in addressing them, and echoes this year’s World Malaria Day theme of ‘Innovate, Invest and Implement’ as the crucial components necessary to end malaria.